CCL2 and chronic kidney disease: The present study evaluated the protective effects of the QC/isoQC inhibitor PQ529 on progressive renal dysfunction in anti-GBM serum–induced glomerulonephritis rats, reinforcing the importance of blocking the CCL2/CCR2 axis for the treatment of CKD and suggesting a novel approach to achieving such blockade.